AI Article Synopsis

Article Abstract

Background: Limited and conflicting data exist regarding the prevalence of psychiatric disorders, particularly substance use disorders (SUDs), among migraineurs in inpatient clinical settings.

Methods: As part of a larger cross-sectional study, 181 substance-dependent inpatients completed a structured psychiatric interview and measures of psychiatric symptoms and migraine. Standardized mean differences were used to quantify differences between inpatients with and without migraine across 4 domains of predictors (demographic variables, non-SUD psychiatric diagnoses, specific SUDs, and self-reported psychiatric symptoms). The predictors within each domain that best discriminated between the migraine and no-migraine groups were identified using a classification tree approach with Bonferroni corrections. These candidate predictors were subsequently entered into a multivariate logistic regression to predict migraine status, which was then replicated using bootstrapping of 500 samples. Associations between migraine status and SUD treatment dropout were also examined.

Results: Forty-four of the 181 (24.3%) participants met criteria for migraine. Migraineurs were more likely to be female (34.8% vs. 18.3%) and reported higher levels of current anxiety symptoms (mean [standard deviation]: 19.7 [11.0] vs. 11.3 [10.3]). Having a lifetime diagnosis of generalized anxiety disorder (56.8% vs. 27%, odds ratio 3.47, 95% confidence interval [CI] 1.39-10.58) or a current diagnosis of alcohol dependence (45.5% vs. 24.1%, odds ratio 3.79, 95% CI 1.63-13.62) was associated with more than a 3-fold risk of migraine. These 4 variables in combination were forced into the final multivariate model, which differentiated well between those with and without migraine (area under the receiver operating characteristic curve = 0.81; 95% CI 0.73-0.88). Migraine was not differentially associated with increased risk for SUD treatment dropout (13.6% vs. 16.1% dropout among those without migraine).

Discussion: A history of generalized anxiety disorder, high levels of current anxiety symptoms, and current alcohol dependence are the strongest psychiatric predictors of migraine status among substance-dependent inpatients. However, migraine status is not associated with SUD treatment dropout.

Download full-text PDF

Source
http://dx.doi.org/10.1111/head.12171DOI Listing

Publication Analysis

Top Keywords

migraine status
16
substance-dependent inpatients
12
sud treatment
12
treatment dropout
12
migraine
11
psychiatric disorders
8
psychiatric symptoms
8
inpatients migraine
8
levels current
8
current anxiety
8

Similar Publications

Mistaken for migraine: Coccidioidal meningitis.

JAAPA

February 2025

At the time this article was written, Anna Morgan was a student in the PA program at the University of North Texas Health Science Center (UNT HSC) in Fort Worth, Tex. She now practices in urgent care at Dignity Health-Mercy Medical Group in Sacramento, Calif. Stephen James Hoyt is a hospitalist at the John Peter Smith Hospital in Fort Worth. Jamie Park practices in emergency medicine and is an assistant professor in the PA program at UNT HSC. Vic Holmes is an associate professor in the PA program at UNT HSC, specializes in the field of family medicine, and is chair of the North Texas Regional Institutional Review Board. The authors have disclosed no potential conflicts of interest, financial or otherwise.

The incidence of coccidioidomycosis has been rising in the past decade. This case report focuses on a man with a history of persistent migraine who presented to the ED with altered mental status. After cerebrospinal fluid testing, the patient was diagnosed with coccidioidal meningitis and treated with lifelong antifungal therapy.

View Article and Find Full Text PDF

Background: Carotenoids are well-established for their potent antioxidant properties; however, their potential association with severe headaches or migraines remains largely unexamined. This study was conducted to explore the relationship between serum carotenoid levels and the prevalence of severe headaches or migraines within the US population.

Methods: We utilized data from the 2001-2004 National Health and Nutrition Examination Survey (NHANES), which comprised a total of 8,910 participants.

View Article and Find Full Text PDF

Valproate, a widely utilized medication for epilepsy, mood disorders, and migraines, has attracted attention for its potential therapeutic benefits extending beyond its traditional uses. This review article compiles recent findings on the expanded utility of valproate outside of epilepsy, mood disorders, and migraines. The review acknowledges conflicting results, discusses opportunities for future research, and underlines both well-established and lesser-known adverse effects, along with possible interventions to mitigate these side effects.

View Article and Find Full Text PDF

Background: Migraine is the most common complex neurological disorder, affecting over a billion people worldwide. Neurogenic inflammation has long been recognized as a key factor in the pathophysiology of migraine though little research has been directed to investigating whether inflammation is greatest in migraine with aura or without, and whether inflammation is a permanent state in migraine or whether is an event related transitory state. Thus, the primary aim of this single-centre, retrospective study was to explore the potential clinical utility of the Serial Systemic Immune-Inflammatory Indices (SSIIi) as a comparative measure of duration and severity of inflammation derived from routine blood cell counts in migraine patients with aura and no-aura both within an acute inpatient setting and as outpatients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!